by April Breyer Menon | Nov 30, 2021
On November 16, 2021, Viatris and Biocon announced the launch of two interchangeable insulin glargine products, a branded version, Semglee® (insulin glargine-yfgn) injection, and an unbranded version, Insulin Glargine (insulin glargine-yfgn) injection, both of which...
by April Breyer Menon | Oct 25, 2021
On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for many of Humira’s approved indications. As an interchangeable, Cyltezo can be automatically substituted for Humira...
by April Breyer Menon | Oct 22, 2021
Ha Kung Wong, Wei Campbell, and Christine Cochran gave a LSPN Live presentation titled “US Patent Legal Landscape Outlook: What are the Main Challenges Facing the US Patent System and how do we Prepare for them?” where they discussed recent Supreme...
by April Breyer Menon | Oct 11, 2021
Christopher Loh taught a Lawline CLE updating in-house and outside counsel on the latest developments in patent case law. The CLE includes a review of the Supreme Court’s Arthrex decision and its effects on the logistics of inter partes review...
by April Breyer Menon | Sep 30, 2021
On September 29, 2021, Senators Patrick Leahy and John Cornyn introduced the Restoring the America Invents Act in the Senate. According to the Senators, the bill seeks to “address problems for small businesses and ordinary Americans caused by poor-quality patents.” ...
by April Breyer Menon | Sep 30, 2021
Lowering drug prices in the U.S. has long been discussed with numerous proposals put forward on steps that could be taken to reach that goal. In July 2021, President Biden issued an Executive Order on Promoting Competition in the American Economy that contained...